Hidden Immune Battle Against Hepatitis B: New Research Reveals Lifelong Viral Fight
For decades, chronic hepatitis B virus (HBV) infections—often acquired at birth—were thought to evade the immune system entirely. A groundbreaking study from the University of Basel challenges this assumption, revealing that the body mounts a sustained, if limited, defense against the virus. The findings, published in Immunity, could pave the way for new therapies targeting immune cells that already engage in this hidden battle.
With over 250 million people worldwide living with chronic HBV, most infected since infancy, the discovery offers fresh hope for treatments that enhance the immune system’s natural efforts rather than starting from scratch.
The Immune System’s “Brakes-On” Response
Contrary to long-held beliefs, researchers found that the immune system doesn’t ignore chronic HBV. Instead, it actively combats the virus—albeit with “the brakes on,” as described by Dr. Katrin Martin, co-first author of the study.
The study identified two critical components of this response:
- Persistent T cell activity: Even in chronic infections, T cells continue to target HBV, though their effectiveness is dampened.
- Partial antibody production: The immune system generates antibodies against the virus, but not at levels sufficient for clearance.
“This changes how we believe about chronic infections that begin early in life,” Martin said. “The immune system isn’t passive—it’s fighting, just not winning.”
How HBV Evades and How the Body Fights Back
The Virus’s Stealth Tactics
HBV employs multiple strategies to avoid immune detection:
- cccDNA persistence: The virus’s covalently closed circular DNA (cccDNA) forms a stable episome in liver cells, evading detection by pattern recognition receptors like cGAS-STING.
- Protein-based suppression: Viral proteins interfere with interferon signaling, a key antiviral defense mechanism.
- Metabolic manipulation: HBV alters cellular metabolism to disrupt immune pathways, such as the RIG-I-like receptor (RLR) pathway.
Recent research in Frontiers in Immunology details how HBV RNA and proteins are detected by toll-like receptors (TLRs) and RIG-I, but the virus counters these defenses through ADAR1 editing and lactate-mediated inhibition of MAVS signaling.
The Body’s Countermeasures
The University of Basel study highlights several immune mechanisms that persist despite viral evasion:
- T helper cells: These cells support antibody production and may be a key target for boosting immune responses.
- Liver-resident macrophages: These cells play a dual role—activating T cells while also expressing immune-suppressive molecules like PD-L1 and IL-10.
- Neutrophils and plasma cells: Recent single-cell RNA sequencing studies, such as one published in Science Bulletin, reveal these cells as part of a network driving transitions between disease phases.
Therapeutic Potential: From Discovery to Treatment
The study’s findings suggest several avenues for future therapies:
- Boosting T helper cells: Enhancing the activity of these cells could improve antibody responses and viral control.
- Targeting immune checkpoints: Blocking molecules like PD-L1, which suppress immune responses, may reinvigorate exhausted T cells.
- Gene editing: Technologies like CRISPR could be used to disrupt cccDNA, the viral reservoir that persists in liver cells.
Dr. Martin emphasized that these approaches could complement existing antiviral therapies, which suppress viral replication but rarely achieve a cure.
The Global Burden of Chronic HBV
Chronic hepatitis B remains a significant public health challenge, particularly in regions with high mother-to-child transmission rates:
- Prevalence: Over 250 million people worldwide are chronically infected, with the highest rates in Asia and Africa.
- Transmission: While modern medicine can prevent perinatal transmission (e.g., through vaccination and antiviral prophylaxis), many infections occur before these interventions are available.
- Disease progression: Chronic HBV can lead to cirrhosis, liver failure, and hepatocellular carcinoma, making it a leading cause of liver-related deaths.
The World Health Organization (WHO) has set a goal to eliminate viral hepatitis as a public health threat by 2030, but achieving this will require advances in both prevention and treatment.
Frequently Asked Questions
1. Why can’t the immune system clear chronic hepatitis B?
Chronic HBV infections often begin at birth, when the immune system is still developing. The virus has evolved multiple mechanisms to evade detection and suppress immune responses, including interfering with interferon signaling and altering cellular metabolism. While the immune system continues to fight the virus, its efforts are insufficient for clearance.
2. How does this research change current treatment approaches?
Current treatments, such as nucleos(t)ide analogs, suppress viral replication but rarely eliminate the virus. This research suggests that therapies could be developed to enhance the immune system’s natural responses, such as boosting T helper cells or blocking immune-suppressive molecules like PD-L1.
3. What are the next steps for this research?
Future studies will likely focus on:
- Developing therapies that target the immune mechanisms identified in the study.
- Exploring gene-editing technologies to disrupt the viral reservoir (cccDNA).
- Conducting clinical trials to test the safety and efficacy of immune-boosting treatments.
4. Can chronic hepatitis B be cured?
A functional cure—where the virus is undetectable and the immune system controls it without medication—is the goal of current research. While rare, some patients achieve this with existing treatments. The new findings could accelerate the development of therapies that increase cure rates.
Looking Ahead: A New Era for HBV Treatment
The discovery of the immune system’s hidden battle against chronic hepatitis B marks a turning point in our understanding of the disease. For the first time, researchers have evidence that the body doesn’t surrender to the virus but continues to fight—albeit with limited success. This insight opens the door to therapies that work with the immune system rather than against it, offering hope for the millions of people living with chronic HBV.
As Dr. Martin noted, “This is just the beginning. We now have a roadmap for developing treatments that could tip the balance in favor of the immune system—and the patient.”